Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Pharmacological AMPK activation induces transcriptional responses congruent to exercise in skeletal and cardiac muscle, adipose tissues and liver.

Muise ES, Guan HP, Liu J, Nawrocki AR, Yang X, Wang C, RodrĂ­guez CG, Zhou D, Gorski JN, Kurtz MM, Feng D, Leavitt KJ, Wei L, Wilkening RR, Apgar JM, Xu S, Lu K, Feng W, Li Y, He H, Previs SF, Shen X, van Heek M, Souza SC, Rosenbach MJ, Biftu T, Erion MD, Kelley DE, Kemp DM, Myers RW, Sebhat IK.

PLoS One. 2019 Feb 27;14(2):e0211568. doi: 10.1371/journal.pone.0211568. eCollection 2019.

2.

Superior Glycemic Control With a Glucose-Responsive Insulin Analog: Hepatic and Nonhepatic Impacts.

Moore MC, Kelley DE, Camacho RC, Zafian P, Ye T, Lin S, Kaarsholm NC, Nargund R, Kelly TM, Van Heek M, Previs SF, Moyes C, Smith MS, Farmer B, Williams P, Cherrington AD.

Diabetes. 2018 Jun;67(6):1173-1181. doi: 10.2337/db18-0099. Epub 2018 Mar 14.

3.

Erratum. Engineering Glucose Responsiveness Into Insulin. Diabetes 2018;67:299-308.

Kaarsholm NC, Lin S, Yan L, Kelly T, van Heek M, Mu J, Wu M, Dai G, Cui Y, Zhu Y, Carballo-Jane E, Reddy V, Zafian P, Huo P, Shi S, Antochshuk V, Ogawa A, Liu F, Souza SC, Seghezzi W, Duffy JL, Erion M, Nargund RP, Kelley DE.

Diabetes. 2018 May;67(5):1030. doi: 10.2337/db18-er05a. Epub 2018 Feb 27. No abstract available.

4.

Engineering Glucose Responsiveness Into Insulin.

Kaarsholm NC, Lin S, Yan L, Kelly T, van Heek M, Mu J, Wu M, Dai G, Cui Y, Zhu Y, Carballo-Jane E, Reddy V, Zafian P, Huo P, Shi S, Antochshuk V, Ogawa A, Liu F, Souza SC, Seghezzi W, Duffy JL, Erion M, Nargund RP, Kelley DE.

Diabetes. 2018 Feb;67(2):299-308. doi: 10.2337/db17-0577. Epub 2017 Nov 2. Erratum in: Diabetes. 2018 Feb 27;:.

5.

Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy.

Myers RW, Guan HP, Ehrhart J, Petrov A, Prahalada S, Tozzo E, Yang X, Kurtz MM, Trujillo M, Gonzalez Trotter D, Feng D, Xu S, Eiermann G, Holahan MA, Rubins D, Conarello S, Niu X, Souza SC, Miller C, Liu J, Lu K, Feng W, Li Y, Painter RE, Milligan JA, He H, Liu F, Ogawa A, Wisniewski D, Rohm RJ, Wang L, Bunzel M, Qian Y, Zhu W, Wang H, Bennet B, LaFranco Scheuch L, Fernandez GE, Li C, Klimas M, Zhou G, van Heek M, Biftu T, Weber A, Kelley DE, Thornberry N, Erion MD, Kemp DM, Sebhat IK.

Science. 2017 Aug 4;357(6350):507-511. doi: 10.1126/science.aah5582. Epub 2017 Jul 13.

PMID:
28705990
6.

Discovery of phenyl acetamides as potent and selective GPR119 agonists.

Zhu C, Wang L, Zhu Y, Guo ZZ, Liu P, Hu Z, Szewczyk JW, Kang L, Chicchi G, Ehrhardt A, Woods A, Seo T, Woods M, van Heek M, Dingley KH, Pang J, Salituro GM, Powell J, Terebetski JL, Hornak V, Campeau LC, Orr RK, Ujjainwalla F, Miller M, Stamford A, Wood HB, Kowalski T, Nargund RP, Edmondson SD.

Bioorg Med Chem Lett. 2017 Mar 1;27(5):1124-1128. doi: 10.1016/j.bmcl.2017.01.091. Epub 2017 Feb 1.

PMID:
28185720
7.

Phenotyping of adipose, liver, and skeletal muscle insulin resistance and response to pioglitazone in spontaneously obese rhesus monkeys.

Shang J, Previs SF, Conarello S, Chng K, Zhu Y, Souza SC, Staup M, Chen Y, Xie D, Zycband E, Schlessinger K, Johnson VP, Arreaza G, Liu F, Levitan D, Wang L, van Heek M, Erion M, Wang Y, Kelley DE.

Am J Physiol Endocrinol Metab. 2017 Apr 1;312(4):E235-E243. doi: 10.1152/ajpendo.00398.2016. Epub 2017 Jan 31.

8.

Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes.

Liu P, Hu Z, DuBois BG, Moyes CR, Hunter DN, Zhu C, Kar NF, Zhu Y, Garfunkle J, Kang L, Chicchi G, Ehrhardt A, Woods A, Seo T, Woods M, van Heek M, Dingley KH, Pang J, Salituro GM, Powell J, Terebetski JL, Hornak V, Campeau LC, Lamberson J, Ujjainwalla F, Miller M, Stamford A, Wood HB, Kowalski T, Nargund RP, Edmondson SD.

ACS Med Chem Lett. 2015 Jul 10;6(8):936-41. doi: 10.1021/acsmedchemlett.5b00207. eCollection 2015 Aug 13.

9.

Development of novel benzomorpholine class of diacylglycerol acyltransferase I inhibitors.

Zhou G, Zorn N, Ting P, Aslanian R, Lin M, Cook J, Lachowicz J, Lin A, Smith M, Hwa J, van Heek M, Walker S.

ACS Med Chem Lett. 2014 Mar 1;5(5):544-9. doi: 10.1021/ml400527n. eCollection 2014 May 8.

10.

Discovery of novel quinoline carboxylic acid series as DGAT1 inhibitors.

Zhou G, Ting PC, Wishart G, Zorn N, Aslanian RG, Lin M, Smith M, Walker SS, Cook J, Van Heek M, Lachowicz J.

Bioorg Med Chem Lett. 2014 Apr 1;24(7):1790-4. doi: 10.1016/j.bmcl.2014.02.028. Epub 2014 Feb 19.

PMID:
24618302
11.

Discovery of XEN445: a potent and selective endothelial lipase inhibitor raises plasma HDL-cholesterol concentration in mice.

Sun S, Dean R, Jia Q, Zenova A, Zhong J, Grayson C, Xie C, Lindgren A, Samra P, Sojo L, van Heek M, Lin L, Percival D, Fu JM, Winther MD, Zhang Z.

Bioorg Med Chem. 2013 Dec 15;21(24):7724-34. doi: 10.1016/j.bmc.2013.10.023. Epub 2013 Oct 28.

PMID:
24211162
12.

Identification of 2-aminooxazole amides as acyl-CoA: diacylglycerol acyltransferase 1 (DGAT1) inhibitors through scaffold hopping strategy.

Kim HM, Smith MD, Kim JH, Caplen MA, Chan TY, McKittrick BA, Cook JA, van Heek M, Lachowicz J.

Bioorg Med Chem Lett. 2013 Dec 1;23(23):6410-4. doi: 10.1016/j.bmcl.2013.09.048. Epub 2013 Sep 25.

PMID:
24120540
13.

Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity.

de Lera Ruiz M, Zheng J, Berlin MY, McCormick KD, Aslanian RG, West R, Hwa J, Lachowicz J, van Heek M.

Bioorg Med Chem Lett. 2013 Nov 1;23(21):6004-9. doi: 10.1016/j.bmcl.2013.08.013. Epub 2013 Aug 19.

PMID:
24035485
14.

Lead optimization of a pyridine-carboxamide series as DGAT-1 inhibitors.

Ting PC, Lee JF, Zorn N, Kim HM, Aslanian RG, Lin M, Smith M, Walker SS, Cook J, Van Heek M, Lachowicz J.

Bioorg Med Chem Lett. 2013 Feb 15;23(4):985-8. doi: 10.1016/j.bmcl.2012.12.040. Epub 2012 Dec 21.

PMID:
23317570
15.

Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1).

Deng Y, Yang Z, Shipps GW Jr, Lo SM, West R, Hwa J, Zheng S, Farley C, Lachowicz J, van Heek M, Bass AS, Sinha DP, Mahon CR, Cartwright ME.

Bioorg Med Chem Lett. 2013 Feb 1;23(3):791-6. doi: 10.1016/j.bmcl.2012.11.075. Epub 2012 Dec 5.

PMID:
23265904
16.

The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans.

Singaraja RR, Sivapalaratnam S, Hovingh K, Dubé MP, Castro-Perez J, Collins HL, Adelman SJ, Riwanto M, Manz J, Hubbard B, Tietjen I, Wong K, Mitnaul LJ, van Heek M, Lin L, Roddy TA, McEwen J, Dallinge-Thie G, van Vark-van der Zee L, Verwoert G, Winther M, van Duijn C, Hofman A, Trip MD, Marais AD, Asztalos B, Landmesser U, Sijbrands E, Kastelein JJ, Hayden MR.

Circ Cardiovasc Genet. 2013 Feb;6(1):54-62. doi: 10.1161/CIRCGENETICS.111.962613. Epub 2012 Dec 14.

17.

Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia.

Palani A, Rao AU, Chen X, Huang X, Su J, Tang H, Huang Y, Qin J, Xiao D, Degrado S, Sofolarides M, Zhu X, Liu Z, McKittrick B, Zhou W, Aslanian R, Greenlee WJ, Senior M, Cheewatrakoolpong B, Zhang H, Farley C, Cook J, Kurowski S, Li Q, van Heek M, Wang G, Hsieh Y, Li F, Greenfeder S, Chintala M.

ACS Med Chem Lett. 2011 Nov 24;3(1):63-8. doi: 10.1021/ml200243g. eCollection 2012 Jan 12.

18.

Discovery of a potent nicotinic Acid receptor agonist for the treatment of dyslipidemia.

Qin J, Rao A, Chen X, Zhu X, Liu Z, Huang X, Degrado S, Huang Y, Xiao D, Aslanian R, Cheewatrakoolpong B, Zhang H, Greenfeder S, Farley C, Cook J, Kurowski S, Li Q, van Heek M, Chintala M, Wang G, Hsieh Y, Li F, Palani A.

ACS Med Chem Lett. 2010 Dec 8;2(2):171-6. doi: 10.1021/ml100251u. eCollection 2011 Feb 10.

19.

Pharmacological profile of the NOP agonist and cough suppressing agent SCH 486757 (8-[Bis(2-Chlorophenyl)Methyl]-3-(2-Pyrimidinyl)-8-Azabicyclo[3.2.1]Octan-3-Ol) in preclinical models.

McLeod RL, Tulshian DB, Bolser DC, Varty GB, Baptista M, Fernandez X, Parra LE, Zimmer JC, Erickson CH, Ho GD, Jia Y, Ng FW, Korfmacher W, Xu X, Veals J, Smith-Torhan A, Wainhaus S, Fawzi AB, Austin TM, van Heek M, Hey JA.

Eur J Pharmacol. 2010 Mar 25;630(1-3):112-20. doi: 10.1016/j.ejphar.2009.12.003. Epub 2009 Dec 16.

20.

Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.

Zheng S, Hoos L, Cook J, Tetzloff G, Davis H Jr, van Heek M, Hwa JJ.

Eur J Pharmacol. 2008 Apr 14;584(1):118-24. doi: 10.1016/j.ejphar.2008.01.045. Epub 2008 Feb 12.

PMID:
18329014
21.

Discovery of novel orally active ureido NPY Y5 receptor antagonists.

Li G, Stamford AW, Huang Y, Cheng KC, Cook J, Farley C, Gao J, Ghibaudi L, Greenlee WJ, Guzzi M, van Heek M, Hwa JJ, Kelly J, Mullins D, Parker EM, Wainhaus S, Zhang X.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):1146-50. Epub 2007 Dec 5.

PMID:
18160282
22.

Tetrahydroisoquinolines as MCH-R1 antagonists.

Sasikumar TK, Qiang L, Wu WL, Burnett DA, Greenlee WJ, O'Neill K, Hawes BE, van Heek M, Graziano M.

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4917-21. Epub 2006 Jul 7.

PMID:
16824753
23.

Biaryl ureas as potent and orally efficacious melanin concentrating hormone receptor 1 antagonists for the treatment of obesity.

Palani A, Shapiro S, McBriar MD, Clader JW, Greenlee WJ, Spar B, Kowalski TJ, Farley C, Cook J, van Heek M, Weig B, O'neill K, Graziano M, Hawes B.

J Med Chem. 2005 Jul 28;48(15):4746-9.

PMID:
16033253
24.

Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats.

van Heek M, Farley C, Compton DS, Hoos LM, Smith-Torhan A, Davis HR.

Br J Pharmacol. 2003 Apr;138(8):1459-64.

25.

Fat intake affects adiposity, comorbidity factors, and energy metabolism of sprague-dawley rats.

Ghibaudi L, Cook J, Farley C, van Heek M, Hwa JJ.

Obes Res. 2002 Sep;10(9):956-63.

26.

Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status.

Parker E, Van Heek M, Stamford A.

Eur J Pharmacol. 2002 Apr 12;440(2-3):173-87. Review.

PMID:
12007534
27.
28.
29.

Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.

van Heek M, Austin TM, Farley C, Cook JA, Tetzloff GG, Davis HR.

Diabetes. 2001 Jun;50(6):1330-5.

30.

The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys.

van Heek M, Compton DS, Davis HR.

Eur J Pharmacol. 2001 Mar 9;415(1):79-84.

PMID:
11245855
31.

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663.

van Heek M, Farley C, Compton DS, Hoos L, Alton KB, Sybertz EJ, Davis HR Jr.

Br J Pharmacol. 2000 Apr;129(8):1748-54.

32.

Cholesteryl hydroperoxyoctadecadienoate from oxidized low density lipoprotein inactivates platelet-derived growth factor.

Van Heek M, Schmitt D, Toren P, Cathcart MK, DiCorleto PE.

J Biol Chem. 1998 Jul 31;273(31):19405-10.

33.

Effect of chronic central administration of glucagon-like peptide-1 (7-36) amide on food consumption and body weight in normal and obese rats.

Davis HR Jr, Mullins DE, Pines JM, Hoos LM, France CF, Compton DS, Graziano MP, Sybertz EJ, Strader CD, Van Heek M.

Obes Res. 1998 Mar;6(2):147-56.

34.

In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461.

Van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, Sybertz EJ, Davis HR Jr.

J Pharmacol Exp Ther. 1997 Oct;283(1):157-63.

PMID:
9336320
35.

Leptin increases energy expenditure and selectively promotes fat metabolism in ob/ob mice.

Hwa JJ, Fawzi AB, Graziano MP, Ghibaudi L, Williams P, Van Heek M, Davis H, Rudinski M, Sybertz E, Strader CD.

Am J Physiol. 1997 Apr;272(4 Pt 2):R1204-9.

PMID:
9140021
36.

Diet-induced obese mice develop peripheral, but not central, resistance to leptin.

Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, Davis HR Jr.

J Clin Invest. 1997 Feb 1;99(3):385-90.

37.

Purification of milligram quantities of human leptin from recombinant E. coli.

Fawzi AB, Zhang H, van Heek M, Graziano MP.

Horm Metab Res. 1996 Dec;28(12):694-7.

PMID:
9013744
38.

The relationship of tissue localization, distribution and turnover to feeding after intraperitoneal 125I-leptin administration to ob/ob and db/db mice.

Van Heek M, Mullins DE, Wirth MA, Graziano MP, Fawzi AB, Compton DS, France CF, Hoos LM, Casale RL, Sybertz EJ, Strader CD, Davis HR Jr.

Horm Metab Res. 1996 Dec;28(12):653-8.

PMID:
9013736
39.

The leptin haemopoietic cytokine fold is stabilized by an intrachain disulfide bond.

Rock FL, Altmann SW, van Heek M, Kastelein RA, Bazan JF.

Horm Metab Res. 1996 Dec;28(12):649-52.

PMID:
9013735
41.

Postprandial lipemia and lipoprotein lipase in the rabbit are modified by olive and coconut oil.

Van Heek M, Zilversmit DB.

Arteriosclerosis. 1990 May-Jun;10(3):421-9.

PMID:
2344299
42.

Supplemental Content

Loading ...
Support Center